- Placebo: no T cell response
- 25ug/25ug No adjuvant: no T cell response
- 5ug/5ug + Matrix M1: Th1 response, some Th2
- 25ug/25ug + Matrix M1: Th1 response, some Th2

Santa Clara University

Overview:
- vaccine had acceptable safety findings and induced high immune responses 
- safe for all people as seen in the study from 5 months to 85 years old
- acceptable candidate to move into Phase 3

Limitations:
- small sample size of the trial
- lack of ethnic diversity
- age was on the younger side
- follow up was short
- participants were generally in good health

Matrix M1 benefit:
- after the second vaccination, neutralizing antibody response was greater than seen in symptomatic covid patients
- the magnitude of antibody and Tcell response
- induction of functional antibodies
- antigen dose sparing
- the two doses of rSARS-CoV-2 with the added Matrix M1 regimen is the best from this clinical trial

Microneutralization testing:
 - the vaccine worked as seen with the anti-spike IgG and microneutralization
- anti-spike IgG and microneutralization titers levels can be correlated to the severity of the disease

Discussion: NVX-CoV2373 Vaccine

Keech, C., Albert, G., Cho, I., Robertson, A., Reed, P., Neal, S., . . . Glenn, G. M. (2020). Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine. New England Journal of Medicine. doi:10.1056/nejmoa2026920
https://www.nejm.org/doi/full/10.1056/NEJMoa2026920

Learn Before

Related